Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...
Medpage Today on MSN1d
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's LymphomaAdding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin ...
Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...
Sufferers who received the standard treatment, a drug called osimertinib, averaged 16.6 months of progression-free survival, the outlet revealed. The findings come as experts reportedly hail a ...
Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...
Discover key gene signatures that could help predict the efficacy of immune checkpoint blockade therapy in patients with ...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaCohort A Data ...
For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...
Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...
Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback